The economic recovery seems on track for slow but steady gains after new reports Tuesday showed growth in manufacturing activity, construction spending and contracts to buy homes.
Pfizer Inc. will spend up to $115 million for rights to an Israeli biotech company's experimental drug and its promising technology for making that drug and others in carrot cells.
Patrick Morris of Hagin Investment Management offers ideas for what stocks would be good to include in a portfolio in 2010, which he says may be challenging for stock investors.
Pfizer will spend up to $115 million for rights to an Israeli biotech company's experimental drug and its promising technology for making that drug and others in carrot cells.
The Swiss branches of Pfizer Inc., Eli Lilly & Co. and Bayer AG were fined a total of 5.7 million francs by competition regulators on Tuesday for alleged price fixing of drugs for erectile dysfunction.
A Goldman Sachs analyst reaffirmed her outlook for Abbott Laboratories and Eli Lilly & Co., but expressed more caution on her respective ratings, citing a mix of drug sales and operating performances in the coming year.
Drug developer Pfizer Inc. is paying Protalix BioTherapeutics Inc. $60 million upfront for licensing rights to a developing Gaucher's disease treatment, the companies said on Tuesday.
The Swiss branches of Pfizer Inc., Eli Lilly & Co. and Bayer AG were fined a total of 5.7 million francs by competition regulators on Tuesday for alleged price fixing of drugs for erectile dysfunction.
NEW YORK----Pfizer and Protalix today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase in development for the potential treatment of Gaucher̢۪s disease.
No comments:
Post a Comment